Phaseline

Targets › PHF8

PHF8 (Histone lysine demethylase PHF8): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Aug 2027.

Histone lysine demethylase with selectivity for mono- and dimethylated residues. It plays an essential role in cell cycle progression and rDNA transcription. (UniProt, Q9UPP1)

Open in Phaseline: the race on PHF8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
InSilico Medicine Hong KongISM5411 (Garutadustat)
PHF8 inhibitor
PHF8Phase 2Ulcerative ColitisAug 2027

Conditions

Ulcerative Colitis (1)

Modalities

small molecule (1)

Companies

InSilico Medicine Hong Kong (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.